By / September 29, 2020

Free Zones could help create a healthy cannabis market in Argentina

The use of medicinal cannabis as a complementary therapy is an idea that has gained ground and popularity worldwide in recent years.

Unfortunately ignorance and prejudices that still fall on cannabis frequently divert the discussion. They take the focus away from what is truly sought: promoting safe accessibility with quality standards to reduce suffering, alleviate pain and generate solutions for patients suffering from certain conditions (such as refractory epilepsy).

In Argentina, Law ‘27,350 [ME1]’ was unanimously approved on March 29, 2017. In its first article, it establishes a regulatory framework for medical and scientific research on the medicinal, therapeutic and / or palliative use of cannabis and its derivatives, guaranteeing and promoting comprehensive health care. But it could do more, such as by authorizing Free Zones toe encourage investment and development in the cannabis sector.

If you want to know more about cannabis, how Argentina could establish free zones in order to develop its cannabis market, and to find out the latest cannabis news, download the mobile application.

Free Zones could be the key to develop the Argentinian cannabis sector

Beneficially for Argentina, some Latin American countries have set precedents and can point to success stories as examples. 

Uruguay, to cite one particularly successful case, has been one of the first countries in the world to obtain a legalized regulatory framework for cannabis, taking advantage of the benefits of the (partially) untaxed ‘free zone’ regime for its production.

Pablo Corgatelli, Uruguayan director of Operal, put the situation in the adjacent country into perspective: 

“Although at first it was notorious for including the regulation of cannabis for recreational use, which can raise questions of various kinds. One of the most interesting aspects of the laws they passed and their regulatory decrees is that they make the production, processing and export of cannabis and hemp for medicinal use viable”.

Regarding its production in free zones, he said: “Today Uruguay has proven knowledge in the entire logistics chain of medicinal cannabis. All these processes can be done by efficiently combining the use of special economic zones. These also give the country important competitive advantages in an export market with an estimated potential of more than one billion dollars annually.”

Free zones not only have competitive advantages, but they can also act as a body that regulates and ensures quality and efficiency standards for the production of cannabis for medicinal use.

Cannabis regulation is needed in order to have a healthy market

“We believe that there is an urgent need for regulation appropriate to the demand of society. People get their own medication where they can at the moment. NGOs have worked a lot with patients trying to guide them, but I believe that the State must provide an answer.” said Silvia Godoy, president of the Bahia branch of the College of Pharmacists.

Godoy also argued that it is time to leave prejudices behind to make room for treatments that can improve people’s quality of life “and that it cannot be omitted that” it is essential to provide traceability to the processes so that the product arrives to patients is safe. Which means being regulated by the State and monitored by the scientific, medical and pharmaceutical communities.

Finally, within the framework of its virtual training cycle, on Wednesday September 30, the regional office in Latam of the World Free Zones Organization will hold a webinar open to the general public, where Latin American specialists will address issues related to the medicinal use of cannabis.

It is expected that participants will learn how cannabis production was implemented in the Free Zones of Colombia and Uruguay, while also talking about the current cannabis legislation and the bills that are being discussed in Argentina.


(Featured image by Herbert Brant via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Cronista, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.

Comments are closed for this post.